- What's Tisch?
- Stem Cell Trial
- Get Involved
The Larry G. Gluck Division of ALS Research located at the Tisch MS Research Center of New York has published research in Brain Communications.
In this study, Tisch researchers developed a first-of-its-kind cerebrospinal fluid-mediated mouse model to identify apolipoprotein B-100 (ApoB) as a key agent causing permanent motor disability, motor neuron degeneration, and other hallmark pathology in sporadic amyotrophic lateral sclerosis (sALS). The research also found that targeted removal of ApoB from sALS cerebrospinal fluid, via filtration or immunodepletion, can prevent this process of motor neuron degeneration, which could potentially be a novel treatment strategy for patients with sALS, the form of ALS that affects 90% of patients.
Additionally, the research was profiled in leading healthcare publication STAT News, in an article that featured interviews with Director and Chief Research Scientist Dr. Saud A. Sadiq and Research Scientist Dr. Jamie Wong.
Read the research paper in Brain Communications here.
Read the feature story in STAT News here.